HomeCompareVCLD vs PFE

VCLD vs PFE: Dividend Comparison 2026

VCLD yields 142857.14% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VCLD wins by $1.703105290929614e+28M in total portfolio value
10 years
VCLD
VCLD
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full VCLD calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — VCLD vs PFE

📍 VCLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCLDPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCLD + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCLD pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCLD
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, VCLD beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCLD + PFE for your $10,000?

VCLD: 50%PFE: 50%
100% PFE50/50100% VCLD
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VCLD
No analyst data
Altman Z
-57.9
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCLD buys
0
PFE buys
0
No recent congressional trades found for VCLD or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCLDPFE
Forward yield142857.14%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.703105290929614e+28M$51.1K
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00$27,210.54
Total dividends collected$1.70295189426983e+28M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VCLD vs PFE ($10,000, DRIP)

YearVCLD PortfolioVCLD Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$14,296,414$14,285,714.29$9,161$701.38+$14.29MVCLD
2$19,102,632,658$19,087,335,494.95$8,610$859.79+$19102.62MVCLD
3$23,856,124,353,624$23,835,684,536,679.88$8,366$1,081.25+$23856124.35MVCLD
4$27,845,102,711,212,050$27,819,576,658,153,670.00$8,483$1,405.66+$27845102711.20MVCLD
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$9,084$1,907.24+$30376787884694.18MVCLD
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$10,418$2,732.78+$30972831647170752.00MVCLD
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$13,007$4,193.56+$29516720240819920896.00MVCLD
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$18,010$7,005.87+$2.6290911335300947e+22MVCLD
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$28,216$12,979.89+$2.1887488081496375e+25MVCLD
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$51,081$27,210.54+$1.703105290929614e+28MVCLD

VCLD vs PFE: Complete Analysis 2026

VCLDStock

Verecloud, Inc. operates as a technology company that provides cloud services in the United States. It develops and operates Cloudwrangler, a cloud service brokerage platform, which connects and integrates cloud service suppliers to small and medium size businesses (SMBs). The company distributes, manages, and bills for cloud services to SMBs. It serves customers directly; and through various distribution channels, including value added resellers, managed service providers, and communication service providers consisting of wireline and wireless telecommunications and cable companies. The company was formerly known as Network Cadence, Inc. and changed its name to Verecloud, Inc. in January 2010. Verecloud, Inc. was founded in 2006 and is headquartered in Englewood, Colorado.

Full VCLD Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VCLD vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCLD vs SCHDVCLD vs JEPIVCLD vs OVCLD vs KOVCLD vs MAINVCLD vs JNJVCLD vs MRKVCLD vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.